T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection
Immunotherapies such as checkpoint-blocking antibodies and adoptive cell transfer are
emerging as treatments for a growing number of cancers. Despite clinical activity of …
emerging as treatments for a growing number of cancers. Despite clinical activity of …
Innate and adaptive immune cells in the tumor microenvironment
TF Gajewski, H Schreiber, YX Fu - Nature immunology, 2013 - nature.com
Most tumor cells express antigens that can mediate recognition by host CD8+ T cells.
Cancers that are detected clinically must have evaded antitumor immune responses to grow …
Cancers that are detected clinically must have evaded antitumor immune responses to grow …
The next hurdle in cancer immunotherapy: overcoming the non–T-cell–inflamed tumor microenvironment
TF Gajewski - Seminars in oncology, 2015 - Elsevier
A growing body of evidence suggests that a major subset of patients with advanced solid
tumors shows evidence for a T-cell–inflamed tumor microenvironment. This phenotype has …
tumors shows evidence for a T-cell–inflamed tumor microenvironment. This phenotype has …
[PDF][PDF] The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures
J Galon, HK Angell, D Bedognetti, FM Marincola - Immunity, 2013 - cell.com
Numerous analyses of large patient cohorts identified specific patterns of immune activation
associated with patient survival. We established these as the immune contexture …
associated with patient survival. We established these as the immune contexture …
Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment
Most cancers express tumor antigens that can be recognized by T cells of the host. The fact
that cancers become clinically evident nonetheless implies that immune escape must occur …
that cancers become clinically evident nonetheless implies that immune escape must occur …
[PDF][PDF] Germline genetic contribution to the immune landscape of cancer
Understanding the contribution of the host's genetic background to cancer immunity may
lead to improved stratification for immunotherapy and to the identification of novel …
lead to improved stratification for immunotherapy and to the identification of novel …
Tumor-intrinsic oncogene pathways mediating immune avoidance
S Spranger, TF Gajewski - Oncoimmunology, 2016 - Taylor & Francis
Immunotherapy is emerging as a major treatment for patients with cancer, predominantly via
blocking immune inhibitory pathways and through adoptive T cell therapy. However, only a …
blocking immune inhibitory pathways and through adoptive T cell therapy. However, only a …
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
Background: Adoptive therapy with tumour-infiltrating lymphocytes (TILs) induces durable
complete responses (CR) in∼ 20% of patients with metastatic melanoma. The recruitment of …
complete responses (CR) in∼ 20% of patients with metastatic melanoma. The recruitment of …
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients
benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable …
benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable …
Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy
Despite recent clinical advances in immunotherapy, a fraction of cancer patients fails to
respond to these interventions. Evidence from preclinical mouse models as well as clinical …
respond to these interventions. Evidence from preclinical mouse models as well as clinical …